Uh-oh! This study is no longer available.
Type 2 Diabetes on Metformin – NAFLD Risk Study
Diabetes (Type 2 Diabetes)
PMG Research of Winston Salem
Approximately 70% of people with diabetes are thought to have some degree of nonalcoholic fatty liver disease (NAFLD), according to the National Institute of Health.
A research study is evaluating an investigational medication for with type 2 diabetes who are at risk for developing NAFLD. This medication may help lower HbA1c levels and reduce fat accumulation in the liver.
This research study may be an option if you:
• Have type 2 diabetes and are on a stable dose of metformin only
• Have an HbA1c between 7 – 10.5%
• Are willing and able to complete MRI scans and FibroScan® (liver ultrasound)
• Have a Body Mass Index (BMI) between 25 - 40. Find out your BMI here http://bmicalculator.cc/
Other criteria apply. Please make sure to discuss with a member of our research staff to ensure this research study is a good fit for you.
Qualified participants will receive all study-related care and study medication or placebo at no cost.
To learn more about NAFLD visit www.pmg-research.com/nash.
Patient Commitment Duration
Approximately 5 months
Financial compensation may be provided for time and travel expenses.
Number of visits in study
Approximately 13 clinic visits and 1 phone call